

JosÃ© L Pedraz Muñoz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4281295/publications.pdf>

Version: 2024-02-01

305
papers

13,221
citations

25034

57
h-index

34986

98
g-index

312
all docs

312
docs citations

312
times ranked

14540
citing authors

#	ARTICLE	IF	CITATIONS
1	From process effluents to intestinal health promotion: Developing biopolymer-whey liposomes loaded with gingerol to heal intestinal wounds and neutralize oxidative stress. <i>International Journal of Pharmaceutics</i> , 2022, 613, 121389.	5.2	3
2	Chondroitin and Dermatan Sulfate Bioinks for 3D Bioprinting and Cartilage Regeneration. <i>Macromolecular Bioscience</i> , 2022, 22, e2100435.	4.1	20
3	Nanodiamond Integration into Niosomes as an Emerging and Efficient Gene Therapy Nanoplatform for Central Nervous System Diseases. <i>ACS Applied Materials & Interfaces</i> , 2022, 14, 13665-13677.	8.0	11
4	Therapeutic Opportunities and Delivery Strategies for Brain Revascularization in Stroke, Neurodegeneration, and Aging. <i>Pharmacological Reviews</i> , 2022, 74, 439-461.	16.0	12
5	Multicomponent Synthesis of Unsaturated $\hat{3}$ -Lactam Derivatives. Applications as Antiproliferative Agents through the Bioisosterism Approach: Carbonyl vs. Phosphoryl Group. <i>Pharmaceutics</i> , 2022, 15, 511.	3.8	7
6	Towards Green Nanoscience: From extraction to nanoformulation. <i>Biotechnology Advances</i> , 2021, 46, 107657.	11.7	30
7	Cell microencapsulation technologies for sustained drug delivery: Clinical trials and companies. <i>Drug Discovery Today</i> , 2021, 26, 852-861.	6.4	11
8	Force Spectroscopy Imaging and Constriction Assays Reveal the Effects of Graphene Oxide on the Mechanical Properties of Alginate Microcapsules. <i>ACS Biomaterials Science and Engineering</i> , 2021, 7, 242-253.	5.2	4
9	Current Insights into 3D Bioprinting: An Advanced Approach for Eye Tissue Regeneration. <i>Pharmaceutics</i> , 2021, 13, 308.	4.5	29
10	GSE4-loaded nanoparticles a potential therapy for lung fibrosis that enhances pneumocyte growth, reduces apoptosis and DNA damage. <i>FASEB Journal</i> , 2021, 35, e21422.	0.5	9
11	Borax-loaded injectable alginate hydrogels promote muscle regeneration in vivo after an injury. <i>Materials Science and Engineering C</i> , 2021, 123, 112003.	7.3	10
12	Characterization of encapsulated porcine cardiosphere-derived cells embedded in 3D alginate matrices. <i>International Journal of Pharmaceutics</i> , 2021, 599, 120454.	5.2	3
13	Design and Validation of a Process Based on Cationic Niosomes for Gene Delivery into Novel Urine-Derived Mesenchymal Stem Cells. <i>Pharmaceutics</i> , 2021, 13, 696.	4.5	3
14	Tendon tissue engineering: Cells, growth factors, scaffolds and production techniques. <i>Journal of Controlled Release</i> , 2021, 333, 448-486.	9.9	70
15	Mesenchymal Stem Cells as a Gene Delivery Tool: Promise, Problems, and Prospects. <i>Pharmaceutics</i> , 2021, 13, 843.	4.5	15
16	How Far Are Non-Viral Vectors to Come of Age and Reach Clinical Translation in Gene Therapy?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7545.	4.1	29
17	Development, characterization and sterilisation of Nanocellulose-alginate-(hyaluronic acid)- bioinks and 3D bioprinted scaffolds for tissue engineering. <i>Materials Science and Engineering C</i> , 2021, 126, 112160.	7.3	38
18	Cell microencapsulation technologies for sustained drug delivery: Latest advances in efficacy and biosafety. <i>Journal of Controlled Release</i> , 2021, 335, 619-636.	9.9	31

#	ARTICLE	IF	CITATIONS
19	Nasal Spray Formulations Based on Combined Hyalurosomes and Glycerosomes Loading Zingiber officinalis Extract as Green and Natural Strategy for the Treatment of Rhinitis and Rhinosinusitis. Antioxidants, 2021, 10, 1109.	5.1	16
20	A Multicomponent Protocol for the Synthesis of Highly Functionalized β -Lactam Derivatives and Their Applications as Antiproliferative Agents. Pharmaceuticals, 2021, 14, 782.	3.8	11
21	Modulation of Conductivity of Alginate Hydrogels Containing Reduced Graphene Oxide through the Addition of Proteins. Pharmaceuticals, 2021, 13, 1473.	4.5	5
22	Benefits of cryopreservation as long-term storage method of encapsulated cardiosphere-derived cells for cardiac therapy: A biomechanical analysis. International Journal of Pharmaceutics, 2021, 607, 121014.	5.2	4
23	Extraction of the antioxidant phytocomplex from wine-making by-products and sustainable loading in phospholipid vesicles specifically tailored for skin protection. Biomedicine and Pharmacotherapy, 2021, 142, 111959.	5.6	25
24	SERS monitoring of local pH in encapsulated therapeutic cells. Nanoscale, 2021, 13, 14354-14362.	5.6	5
25	Complementary effect of Zingiber officinalis extract and citral in counteracting non allergic nasal congestion by simultaneous loading in ad hoc formulated phospholipid vesicles. Colloids and Surfaces B: Biointerfaces, 2021, 209, 112170.	5.0	0
26	Oleuropein multicompartiment nanovesicles enriched with collagen as a natural strategy for the treatment of skin wounds connected with oxidative stress. Nanomedicine, 2021, 16, 2363-2376.	3.3	11
27	Sphingolipid extracts enhance gene delivery of cationic lipid vesicles into retina and brain. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 169, 103-112.	4.3	9
28	Clay Minerals as Bioink Ingredients for 3D Printing and 3D Bioprinting: Application in Tissue Engineering and Regenerative Medicine. Pharmaceuticals, 2021, 13, 1806.	4.5	18
29	Correlation between Biophysical Properties of Niosomes Elaborated with Chloroquine and Different Tensioactives and Their Transfection Efficiency. Pharmaceuticals, 2021, 13, 1787.	4.5	7
30	Intrapericardial Delivery of APA-Microcapsules as Promising Stem Cell Therapy Carriers in an Experimental Acute Myocardial Infarction Model. Pharmaceuticals, 2021, 13, 1824.	4.5	1
31	Design of a Nasal Spray Based on Cardiospermum halicacabum Extract Loaded in Phospholipid Vesicles Enriched with Gelatin or Chondroitin Sulfate. Molecules, 2021, 26, 6670.	3.8	1
32	Excipient-Free Inhalable Microparticles of Azithromycin Produced by Electrospray: A Novel Approach to Direct Pulmonary Delivery of Antibiotics. Pharmaceuticals, 2021, 13, 1988.	4.5	3
33	Evaluation of Glycerolphytate Crosslinked Semi- and Interpenetrated Polymer Membranes of Hyaluronic Acid and Chitosan for Tissue Engineering. Polymers, 2020, 12, 2661.	4.5	11
34	Non-viral mediated gene therapy in human cystic fibrosis airway epithelial cells recovers chloride channel functionality. International Journal of Pharmaceutics, 2020, 588, 119757.	5.2	15
35	Extraction, Characterization and Incorporation of Hypericum scruglii Extract in Ad Hoc Formulated Phospholipid Vesicles Designed for the Treatment of Skin Diseases Connected with Oxidative Stress. Pharmaceuticals, 2020, 12, 1010.	4.5	12
36	Encapsulation of Oleuropein in Nanostructured Lipid Carriers: Biocompatibility and Antioxidant Efficacy in Lung Epithelial Cells. Pharmaceuticals, 2020, 12, 429.	4.5	36

#	ARTICLE	IF	CITATIONS
37	Oral delivery of oleuropein-loaded lipid nanocarriers alleviates inflammation and oxidative stress in acute colitis. <i>International Journal of Pharmaceutics</i> , 2020, 586, 119515.	5.2	40
38	Graphene oxide and reduced graphene oxide-based scaffolds in regenerative medicine. <i>International Journal of Pharmaceutics</i> , 2020, 580, 119226.	5.2	143
39	Niosome-Based Approach for In Situ Gene Delivery to Retina and Brain Cortex as Immune-Privileged Tissues. <i>Pharmaceutics</i> , 2020, 12, 198.	4.5	34
40	BSA- and Elastin-Coated GO, but Not Collagen-Coated GO, Enhance the Biological Performance of Alginate Hydrogels. <i>Pharmaceutics</i> , 2020, 12, 543.	4.5	5
41	iPSC-Derived Intestinal Organoids from Cystic Fibrosis Patients Acquire CFTR Activity upon TALEN-Mediated Repair of the p.F508del Mutation. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 17, 858-870.	4.1	35
42	Development and validation of an eco-friendly HPLC-DAD method for the determination of oleuropein and its applicability to several matrices: olive oil, olive leaf extracts and nanostructured lipid carriers. <i>Green Chemistry</i> , 2020, 22, 3495-3505.	9.0	8
43	Brain Angiogenesis Induced by Nonviral Gene Therapy with Potential Therapeutic Benefits for Central Nervous System Diseases. <i>Molecular Pharmaceutics</i> , 2020, 17, 1848-1858.	4.6	9
44	Clinical Applications of Cell Encapsulation Technology. <i>Methods in Molecular Biology</i> , 2020, 2100, 473-491.	0.9	9
45	Immobilization of INS1E Insulin-Producing Cells Within Injectable Alginate Hydrogels. <i>Methods in Molecular Biology</i> , 2020, 2100, 395-405.	0.9	1
46	Monitoring implantable immunoisolation devices with intrinsic fluorescence of genipin. <i>Journal of Biophotonics</i> , 2019, 12, e201800170.	2.3	4
47	Advances in cell-laden hydrogels for delivering therapeutics. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1219-1222.	3.1	3
48	Cationic niosome-based hBMP7 gene transfection of neuronal precursor NT2 cells to reduce the migration of glioma cells in vitro. <i>Journal of Drug Delivery Science and Technology</i> , 2019, 53, 101219.	3.0	10
49	Cationic Niosomes as Non-Viral Vehicles for Nucleic Acids: Challenges and Opportunities in Gene Delivery. <i>Pharmaceutics</i> , 2019, 11, 50.	4.5	59
50	3D printed polyamide macroencapsulation devices combined with alginate hydrogels for insulin-producing cell-based therapies. <i>International Journal of Pharmaceutics</i> , 2019, 566, 604-614.	5.2	14
51	Gene delivery to the rat retina by non-viral vectors based on chloroquine-containing cationic niosomes. <i>Journal of Controlled Release</i> , 2019, 304, 181-190.	9.9	38
52	Recent advances in gelatin-based therapeutics. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 773-779.	3.1	85
53	Safety and effectiveness of sodium colistimethate-loaded nanostructured lipid carriers (SCM-NLC) against <i>P. aeruginosa</i> : in vitro and in vivo studies following pulmonary and intramuscular administration. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 18, 101-111.	3.3	22
54	Enzymatic crosslinked gelatin 3D scaffolds for bone tissue engineering. <i>International Journal of Pharmaceutics</i> , 2019, 562, 151-161.	5.2	46

#	ARTICLE	IF	CITATIONS
55	Non-viral vectors based on cationic niosomes and minicircle DNA technology enhance gene delivery efficiency for biomedical applications in retinal disorders. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 17, 308-318.	3.3	39
56	Type 1 Diabetes Mellitus reversal via implantation of magnetically purified microencapsulated pseudoislets. <i>International Journal of Pharmaceutics</i> , 2019, 560, 65-77.	5.2	12
57	Review of Advanced Hydrogel-Based Cell Encapsulation Systems for Insulin Delivery in Type 1 Diabetes Mellitus. <i>Pharmaceutics</i> , 2019, 11, 597.	4.5	56
58	Force spectroscopy-based simultaneous topographical and mechanical characterization to study polymer-to-polymer interactions in coated alginate microspheres. <i>Scientific Reports</i> , 2019, 9, 20112.	3.3	9
59	Biphasic Hydrogels Integrating Mineralized and Anisotropic Features for Interfacial Tissue Engineering. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 47771-47784.	8.0	40
60	Hyaluronic acid enhances cell survival of encapsulated insulin-producing cells in alginate-based microcapsules. <i>International Journal of Pharmaceutics</i> , 2019, 557, 192-198.	5.2	34
61	Hyaluronic Acid Promotes Differentiation of Mesenchymal Stem Cells from Different Sources toward Pancreatic Progenitors within Three-Dimensional Alginate Matrixes. <i>Molecular Pharmaceutics</i> , 2019, 16, 834-845.	4.6	15
62	Sorbitol-penetration enhancer containing vesicles loaded with baicalin for the protection and regeneration of skin injured by oxidative stress and UV radiation. <i>International Journal of Pharmaceutics</i> , 2019, 555, 175-183.	5.2	20
63	3D cell-laden polymers to release bioactive products in the eye. <i>Progress in Retinal and Eye Research</i> , 2019, 68, 67-82.	15.5	15
64	Beneficial effects of n-3 polyunsaturated fatty acids administration in a partial lesion model of Parkinson's disease: The role of glia and Nrf2 regulation. <i>Neurobiology of Disease</i> , 2019, 121, 252-262.	4.4	67
65	Engineering a Clinically Translatable Bioartificial Pancreas to Treat Type I Diabetes. <i>Trends in Biotechnology</i> , 2018, 36, 445-456.	9.3	62
66	Microencapsulated macrophages releases conditioned medium able to prevent epithelial to mesenchymal transition. <i>Drug Delivery</i> , 2018, 25, 91-101.	5.7	3
67	Current advanced therapy cell-based medicinal products for type-1-diabetes treatment. <i>International Journal of Pharmaceutics</i> , 2018, 543, 107-120.	5.2	17
68	Characterization of an encapsulated insulin secreting human pancreatic beta cell line in a modular microfluidic device. <i>Journal of Drug Targeting</i> , 2018, 26, 36-44.	4.4	15
69	Tunable injectable alginate-based hydrogel for cell therapy in Type 1 Diabetes Mellitus. <i>International Journal of Biological Macromolecules</i> , 2018, 107, 1261-1269.	7.5	58
70	Autologous bioscaffolds based on different concentrations of platelet rich plasma and synovial fluid as a vehicle for mesenchymal stem cells. <i>Journal of Biomedical Materials Research - Part A</i> , 2018, 106, 377-385.	4.0	3
71	Alginate Microcapsules for Drug Delivery. <i>Springer Series in Biomaterials Science and Engineering</i> , 2018, , 67-100.	1.0	11
72	Stem cell-based gene delivery mediated by cationic niosomes for bone regeneration. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 521-531.	3.3	36

#	ARTICLE	IF	CITATIONS
73	Hyaluronic acid hydrogel scaffolds loaded with cationic niosomes for efficient non-viral gene delivery. RSC Advances, 2018, 8, 31934-31942.	3.6	29
74	Gene transfer to rat cerebral cortex mediated by polysorbate 80 and poloxamer 188 nonionic surfactant vesicles. Drug Design, Development and Therapy, 2018, Volume 12, 3937-3949.	4.3	12
75	Non-viral vectors based on cationic niosomes as efficient gene delivery vehicles to central nervous system cells into the brain. International Journal of Pharmaceutics, 2018, 552, 48-55.	5.2	30
76	The Role of Lipid Nanoparticles and its Surface Modification in Reaching the Brain: An Approach for Neurodegenerative Diseases Treatment. Current Drug Delivery, 2018, 15, 1218-1220.	1.6	3
77	Polysorbate 20 non-ionic surfactant enhances retinal gene delivery efficiency of cationic niosomes after intravitreal and subretinal administration. International Journal of Pharmaceutics, 2018, 550, 388-397.	5.2	28
78	Graphene oxide enhances alginate encapsulated cells viability and functionality while not affecting the foreign body response. Drug Delivery, 2018, 25, 1147-1160.	5.7	25
79	Advances in the slow freezing cryopreservation of microencapsulated cells. Journal of Controlled Release, 2018, 281, 119-138.	9.9	48
80	3D Printed porous polyamide macrocapsule combined with alginate microcapsules for safer cell-based therapies. Scientific Reports, 2018, 8, 8512.	3.3	25
81	Low molecular-weight hyaluronan as a cryoprotectant for the storage of microencapsulated cells. International Journal of Pharmaceutics, 2018, 548, 206-216.	5.2	4
82	Preparation and Characterization of Resveratrol Loaded Pectin/Alginate Blend Gastro-Resistant Microparticles. Molecules, 2018, 23, 1886.	3.8	16
83	Intranasal Administration of TAT-Conjugated Lipid Nanocarriers Loading GDNF for Parkinson's Disease. Molecular Neurobiology, 2018, 55, 145-155.	4.0	95
84	Gene delivery to the lungs: pulmonary gene therapy for cystic fibrosis. Drug Development and Industrial Pharmacy, 2017, 43, 1071-1081.	2.0	23
85	Hybrid Alginate-Protein-Coated Graphene Oxide Microcapsules Enhance the Functionality of Erythropoietin Secreting C ₂ C ₁₂ Myoblasts. Molecular Pharmaceutics, 2017, 14, 885-898.	4.6	13
86	Non-viral vectors based on magnetoplexes, lipoplexes and polyplexes for VEGF gene delivery into central nervous system cells. International Journal of Pharmaceutics, 2017, 521, 130-140.	5.2	19
87	Biologically active and biomimetic dual gelatin scaffolds for tissue engineering. International Journal of Biological Macromolecules, 2017, 98, 486-494.	7.5	24
88	Nanotechnology-based delivery systems to release growth factors and other endogenous molecules for chronic wound healing. Journal of Drug Delivery Science and Technology, 2017, 42, 2-17.	3.0	28
89	Progress of gelatin-based 3D approaches for bone regeneration. Journal of Drug Delivery Science and Technology, 2017, 42, 63-74.	3.0	89
90	Alginate Microcapsules Incorporating Hyaluronic Acid Recreate Closer <i>in Vivo</i> Environment for Mesenchymal Stem Cells. Molecular Pharmaceutics, 2017, 14, 2390-2399.	4.6	28

#	ARTICLE	IF	CITATIONS
91	Cell microencapsulation technology: Current vision of its therapeutic potential through the administration routes. <i>Journal of Drug Delivery Science and Technology</i> , 2017, 42, 49-62.	3.0	30
92	Retinal gene delivery enhancement by lycopene incorporation into cationic niosomes based on DOTMA and polysorbate 60. <i>Journal of Controlled Release</i> , 2017, 254, 55-64.	9.9	54
93	Amine containing cationic methacrylate copolymers as efficient gene delivery vehicles to retinal epithelial cells. <i>Journal of Polymer Science Part A</i> , 2017, 55, 280-287.	2.3	4
94	Improved control over MSCs behavior within 3D matrices by using different cell loads in both in vitro and in vivo environments. <i>International Journal of Pharmaceutics</i> , 2017, 533, 62-72.	5.2	4
95	Cationic nioplexes-in-polysaccharide-based hydrogels as versatile biodegradable hybrid materials to deliver nucleic acids. <i>Journal of Materials Chemistry B</i> , 2017, 5, 7756-7767.	5.8	12
96	Ultra thin hydro-films based on lactose-crosslinked fish gelatin for wound healing applications. <i>International Journal of Pharmaceutics</i> , 2017, 530, 455-467.	5.2	36
97	Cryopreservation of Human Mesenchymal Stem Cells in an Allogeneic Bioscaffold based on Platelet Rich Plasma and Synovial Fluid. <i>Scientific Reports</i> , 2017, 7, 15733.	3.3	20
98	The role of osmolarity adjusting agents in the regulation of encapsulated cell behavior to provide a safer and more predictable delivery of therapeutics. <i>Drug Delivery</i> , 2017, 24, 1654-1666.	5.7	13
99	Novel nanofibrous dressings containing rhEGF and Aloe vera for wound healing applications. <i>International Journal of Pharmaceutics</i> , 2017, 523, 556-566.	5.2	145
100	Use of Flow Focusing Technique for Microencapsulation of Myoblasts. <i>Methods in Molecular Biology</i> , 2017, 1479, 207-216.	0.9	2
101	Microencapsulated Cells for Cancer Therapy. <i>Methods in Molecular Biology</i> , 2017, 1479, 261-272.	0.9	2
102	Free and Nanoencapsulated Tobramycin: Effects on Planktonic and Biofilm Forms of <i>Pseudomonas</i> . <i>Microorganisms</i> , 2017, 5, 35.	3.6	21
103	Determination of the spatiotemporal dependence of <i>Pseudomonas aeruginosa</i> biofilm viability after treatment with NLC-colistin. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 4409-4413.	6.7	18
104	Benznidazole Nanoformulates: A Chance to Improve Therapeutics for Chagas Disease. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 97, 1469-1476.	1.4	30
105	Nanotechnology Based Approaches for Neurodegenerative Disorders: Diagnosis and Treatment. , 2017, , 57-87.		3
106	Nanotechnology-based drug-delivery systems releasing growth factors to the CNS. , 2016, , 371-402.		3
107	Intranasal Administration of Chitosan-Coated Nanostructured Lipid Carriers Loaded with GDNF Improves Behavioral and Histological Recovery in a Partial Lesion Model of Parkinson's Disease. <i>Journal of Biomedical Nanotechnology</i> , 2016, 12, 2220-2280.	1.1	65
108	The Use of Nanoparticles for Antimicrobial Delivery. , 2016, , 453-487.		2

#	ARTICLE	IF	CITATIONS
109	Advances in nanomedicine for the treatment of Alzheimer's and Parkinson's diseases. <i>Nanomedicine</i> , 2016, 11, 1267-1285.	3.3	35
110	LL37 loaded nanostructured lipid carriers (NLC): A new strategy for the topical treatment of chronic wounds. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2016, 108, 310-316.	4.3	76
111	Nioplexes encapsulated in supramolecular hybrid hydrogels as versatile delivery platforms for nucleic acids. <i>RSC Advances</i> , 2016, 6, 39688-39699.	3.6	12
112	Stability study of sodium colistimethate-loaded lipid nanoparticles. <i>Journal of Microencapsulation</i> , 2016, 33, 636-645.	2.8	18
113	Pulmonary delivery of tobramycin-loaded nanostructured lipid carriers for <i>Pseudomonas aeruginosa</i> infections associated with cystic fibrosis. <i>International Journal of Pharmaceutics</i> , 2016, 498, 263-273.	5.2	61
114	Killing effect of nanoencapsulated colistin sulfate on <i>Pseudomonas aeruginosa</i> from cystic fibrosis patients. <i>Journal of Cystic Fibrosis</i> , 2016, 15, 611-618.	0.7	55
115	The role of helper lipids in the intracellular disposition and transfection efficiency of niosome formulations for gene delivery to retinal pigment epithelial cells. <i>International Journal of Pharmaceutics</i> , 2016, 503, 115-126.	5.2	34
116	Nanotechnology approaches for skin wound regeneration using drug-delivery systems. , 2016, , 31-55.		10
117	Nanoparticle transport across in vitro olfactory cell monolayers. <i>International Journal of Pharmaceutics</i> , 2016, 499, 81-89.	5.2	81
118	The influence of the polar head-group of synthetic cationic lipids on the transfection efficiency mediated by niosomes in rat retina and brain. <i>Biomaterials</i> , 2016, 77, 267-279.	11.4	59
119	Optoacoustic imaging enabled biodistribution study of cationic polymeric biodegradable nanoparticles. <i>Contrast Media and Molecular Imaging</i> , 2015, 10, 421-427.	0.8	8
120	Specific requirements regarding module 5. <i>Pharmaceuticals Policy and Law</i> , 2015, 17, 279-281.	0.1	0
121	Development and in vitro evaluation of lipid nanoparticle-based dressings for topical treatment of chronic wounds. <i>International Journal of Pharmaceutics</i> , 2015, 490, 404-411.	5.2	29
122	Development and validation of a bioanalytical method for the simultaneous determination of heroin, its main metabolites, naloxone and naltrexone by LC-MS/MS in human plasma samples: Application to a clinical trial of oral administration of a heroin/naloxone formulation. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 114, 105-112.	2.8	15
123	Assessment of the Behavior of Mesenchymal Stem Cells Immobilized in Biomimetic Alginate Microcapsules. <i>Molecular Pharmaceutics</i> , 2015, 12, 3953-3962.	4.6	22
124	Delivery of an adenovirus vector plasmid by ultrapure oligochitosan based polyplexes. <i>International Journal of Pharmaceutics</i> , 2015, 479, 312-319.	5.2	5
125	Enduring high-efficiency in vivo transfection of neurons with non-viral magnetoparticles in the rat visual cortex for optogenetic applications. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 835-843.	3.3	28
126	Advances in cell encapsulation technology and its application in drug delivery. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 1251-1267.	5.0	31

#	ARTICLE	IF	CITATIONS
127	Cryopreservation of microencapsulated murine mesenchymal stem cells genetically engineered to secrete erythropoietin. <i>International Journal of Pharmaceutics</i> , 2015, 485, 15-24.	5.2	32
128	Development of surface modified biodegradable polymeric nanoparticles to deliver GSE24.2 peptide to cells: A promising approach for the treatment of defective telomerase disorders. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2015, 91, 91-102.	4.3	25
129	Graphene oxide increases the viability of C2C12 myoblasts microencapsulated in alginate. <i>International Journal of Pharmaceutics</i> , 2015, 493, 260-270.	5.2	34
130	Pulmonary drug delivery: a review on nanocarriers for antibacterial chemotherapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2945-2955.	3.0	68
131	Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration. <i>Colloids and Surfaces B: Biointerfaces</i> , 2015, 134, 304-313.	5.0	135
132	Specific requirements for somatic cell therapy medicinal products and tissue engineered products. <i>Pharmaceuticals Policy and Law</i> , 2015, 17, 271-277.	0.1	0
133	Cell encapsulation: technical and clinical advances. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 537-546.	8.7	151
134	Advances in drug delivery systems (DDSs) to release growth factors for wound healing and skin regeneration. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 1551-1573.	3.3	211
135	Evaluation of different RGD ligand densities in the development of cell-based drug delivery systems. <i>Journal of Drug Targeting</i> , 2015, 23, 806-812.	4.4	14
136	Improving transfection efficiency of ultrapure oligochitosan/DNA polyplexes by medium acidification. <i>Drug Delivery</i> , 2015, 22, 100-110.	5.7	23
137	New Insights into Gene Delivery to Human Neuronal Precursor NT2 Cells: A Comparative Study between Lipoplexes, Nioplexes, and Polyplexes. <i>Molecular Pharmaceutics</i> , 2015, 12, 4056-4066.	4.6	19
138	Design and evaluation of surface and adjuvant modified PLGA microspheres for uptake by dendritic cells to improve vaccine responses. <i>International Journal of Pharmaceutics</i> , 2015, 496, 371-381.	5.2	30
139	Topographical Distribution of Morphological Changes in a Partial Model of Parkinson's Disease: Effects of Nanoencapsulated Neurotrophic Factors Administration. <i>Molecular Neurobiology</i> , 2015, 52, 846-858.	4.0	18
140	Protamine/DNA/Niosome Ternary Nonviral Vectors for Gene Delivery to the Retina: The Role of Protamine. <i>Molecular Pharmaceutics</i> , 2015, 12, 3658-3671.	4.6	39
141	Microencapsulation of therapeutic bispecific antibodies producing cells: immunotherapeutic organoids for cancer management. <i>Journal of Drug Targeting</i> , 2015, 23, 170-179.	4.4	24
142	The topical administration of rhEGF-loaded nanostructured lipid carriers (rhEGF-NLC) improves healing in a porcine full-thickness excisional wound model. <i>Journal of Controlled Release</i> , 2015, 197, 41-47.	9.9	100
143	Niosomes based on synthetic cationic lipids for gene delivery: the influence of polar head-groups on the transfection efficiency in HEK-293, ARPE-19 and MSC-D1 cells. <i>Organic and Biomolecular Chemistry</i> , 2015, 13, 1068-1081.	2.8	50
144	Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson's disease. <i>International Journal of Nanomedicine</i> , 2014, 9, 2677.	6.7	42

#	ARTICLE	IF	CITATIONS
145	Cellulose acetate phthalate microparticles containing <i>Vibrio cholerae</i> : steps toward an oral cholera vaccine. <i>Journal of Drug Targeting</i> , 2014, 22, 478-487.	4.4	17
146	Low Molecular Weight Chitosan (LMWC)-based Polyplexes for pDNA Delivery: From Bench to Bedside. <i>Polymers</i> , 2014, 6, 1727-1755.	4.5	46
147	The synergistic effects of the RGD density and the microenvironment on the behavior of encapsulated cells: In vitro and in vivo direct comparative study. <i>Journal of Biomedical Materials Research - Part A</i> , 2014, 102, 3965-3972.	4.0	16
148	Behaviour and ultrastructure of human bone marrow-derived mesenchymal stem cells immobilised in alginate-poly-L-lysine-alginate microcapsules. <i>Journal of Microencapsulation</i> , 2014, 31, 579-589.	2.8	17
149	Repeated dose toxicity study of <i>Vibrio cholerae</i> -loaded gastro-resistant microparticles. <i>Journal of Microencapsulation</i> , 2014, 31, 86-92.	2.8	9
150	Application of cell encapsulation for controlled delivery of biological therapeutics. <i>Advanced Drug Delivery Reviews</i> , 2014, 67-68, 3-14.	13.7	100
151	A Novel Formulation Based on 2,3-Di(tetradecyloxy)propan-1-amine Cationic Lipid Combined with Polysorbate 80 for Efficient Gene Delivery to the Retina. <i>Pharmaceutical Research</i> , 2014, 31, 1665-1675.	3.5	19
152	Nanotherapeutic approaches for brain cancer management. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2014, 10, e905-e919.	3.3	87
153	A novel cationic niosome formulation for gene delivery to the retina. <i>Journal of Controlled Release</i> , 2014, 174, 27-36.	9.9	128
154	Development and validation of a rapid HPLC method for the quantification of GSE4 peptide in biodegradable PEI-PLGA nanoparticles. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 972, 95-101.	2.3	4
155	Sodium colistimethate loaded lipid nanocarriers for the treatment of <i>Pseudomonas aeruginosa</i> infections associated with cystic fibrosis. <i>International Journal of Pharmaceutics</i> , 2014, 477, 485-494.	5.2	56
156	Advanced nanovehicles for cancer management. <i>Drug Discovery Today</i> , 2014, 19, 1659-1670.	6.4	43
157	A novel strategy for the treatment of chronic wounds based on the topical administration of rhEGF-loaded lipid nanoparticles: In vitro bioactivity and in vivo effectiveness in healing-impaired db/db mice. <i>Journal of Controlled Release</i> , 2014, 185, 51-61.	9.9	143
158	Multifunctional hydrogel-based scaffold for improving the functionality of encapsulated therapeutic cells and reducing inflammatory response. <i>Acta Biomaterialia</i> , 2014, 10, 4206-4216.	8.3	29
159	Cationic vesicles based on non-ionic surfactant and synthetic aminolipids mediate delivery of antisense oligonucleotides into mammalian cells. <i>Colloids and Surfaces B: Biointerfaces</i> , 2014, 119, 30-37.	5.0	18
160	Designing improved poly lactic-co-glycolic acid microspheres for a malarial vaccine: incorporation of alginate and polyinosinic-polycytidilic acid. <i>Journal of Microencapsulation</i> , 2014, 31, 560-566.	2.8	6
161	Encapsulation of Cells in Alginate Gels. <i>Methods in Molecular Biology</i> , 2013, 1051, 313-325.	0.9	11
162	Oligochitosan polyplexes as carriers for retinal gene delivery. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 48, 323-331.	4.0	31

#	ARTICLE	IF	CITATIONS
163	The state-of-the-art of approved and under-development cholera vaccines. <i>Vaccine</i> , 2013, 31, 4069-4078.	3.8	27
164	VEGF-releasing biodegradable nanospheres administered by craniotomy: A novel therapeutic approach in the APP/Ps1 mouse model of Alzheimer's disease. <i>Journal of Controlled Release</i> , 2013, 170, 111-119.	9.9	56
165	Biomedical Applications of Immobilized Enzymes: An Update. <i>Methods in Molecular Biology</i> , 2013, 1051, 285-299.	0.9	6
166	Therapeutic Applications of Encapsulated Cells. <i>Methods in Molecular Biology</i> , 2013, 1051, 349-364.	0.9	13
167	Low molecular weight oligochitosans for non-viral retinal gene therapy. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2013, 83, 131-140.	4.3	46
168	Hydrogel-Based Scaffolds for Enclosing Encapsulated Therapeutic Cells. <i>Biomacromolecules</i> , 2013, 14, 322-330.	5.4	18
169	rhEGF-loaded PLGA-Alginate microspheres enhance the healing of full-thickness excisional wounds in diabetised Wistar rats. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 50, 243-252.	4.0	61
170	In vivo administration of VEGF- and GDNF-releasing biodegradable polymeric microspheres in a severe lesion model of Parkinson's disease. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2013, 85, 1183-1190.	4.3	58
171	A preliminary approach to the repair of myocardial infarction using adipose tissue-derived stem cells encapsulated in magnetic resonance-labelled alginate microspheres in a porcine model. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2013, 84, 29-39.	4.3	38
172	Therapeutic cell encapsulation: Ten steps towards clinical translation. <i>Journal of Controlled Release</i> , 2013, 170, 1-14.	9.9	75
173	An approach to a cold chain free oral cholera vaccine: in vitro and in vivo characterization of <i>Vibrio cholerae</i> gastro-resistant microparticles. <i>International Journal of Pharmaceutics</i> , 2013, 448, 247-258.	5.2	27
174	Inactivation of encapsulated cells and their therapeutic effects by means of TGL triple-fusion reporter/biosafety gene. <i>Biomaterials</i> , 2013, 34, 1442-1451.	11.4	16
175	Malaria Vaccine Adjuvants: Latest Update and Challenges in Preclinical and Clinical Research. <i>BioMed Research International</i> , 2013, 2013, 1-19.	1.9	35
176	Plasmodium falciparum malaria vaccines: current status, pitfalls and future directions. <i>Expert Review of Vaccines</i> , 2012, 11, 1071-1086.	4.4	11
177	Encapsulated VEGF-Secreting Cells Enhance Proliferation of Neuronal Progenitors in the Hippocampus of A β 2PP/Ps1 Mice. <i>Journal of Alzheimer's Disease</i> , 2012, 29, 187-200.	2.6	30
178	Combination of immune stimulating adjuvants with poly(lactide-co-glycolide) microspheres enhances the immune response of vaccines. <i>Vaccine</i> , 2012, 30, 589-596.	3.8	37
179	Stem cells in alginate bioscaffolds. <i>Therapeutic Delivery</i> , 2012, 3, 761-774.	2.2	18
180	Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research. <i>Clinical and Translational Oncology</i> , 2012, 14, 83-93.	2.4	239

#	ARTICLE	IF	CITATIONS
181	Novel advances in the design of three-dimensional bio-scaffolds to control cell fate: translation from 2D to 3D. <i>Trends in Biotechnology</i> , 2012, 30, 331-341.	9.3	121
182	Optimization of 100 μ m alginate-poly-L-lysine-alginate capsules for intravitreal administration. <i>Journal of Controlled Release</i> , 2012, 158, 443-450.	9.9	36
183	Pharmacokinetic/pharmacodynamic evaluation of amoxicillin, amoxicillin/clavulanate and ceftriaxone in the treatment of paediatric acute otitis media in Spain. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2011, 29, 167-173.	0.5	22
184	Novel extended-release formulation of lovastatin by one-step melt granulation: In vitro and in vivo evaluation. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2011, 77, 306-312.	4.3	24
185	A new oral vaccine candidate based on the microencapsulation by spray-drying of inactivated <i>Vibrio cholerae</i> . <i>Vaccine</i> , 2011, 29, 5758-5764.	3.8	39
186	Enhancing immunogenicity to PLGA microparticulate systems by incorporation of alginate and RGD-modified alginate. <i>European Journal of Pharmaceutical Sciences</i> , 2011, 44, 32-40.	4.0	48
187	Encapsulation of β -galactosidase in PLGA microparticles enhances serum antibody response in mice immunized by subcutaneous and intranasal routes. <i>European Journal of Pharmaceutical Sciences</i> , 2011, 44, 200-206.	4.0	16
188	Emerging technologies in the delivery of erythropoietin for therapeutics. <i>Medicinal Research Reviews</i> , 2011, 31, 284-309.	10.5	20
189	Design of a composite drug delivery system to prolong functionality of cell-based scaffolds. <i>International Journal of Pharmaceutics</i> , 2011, 407, 142-150.	5.2	32
190	An Overview on the Field of Micro- and Nanotechnologies for Synthetic Peptide-Based Vaccines. <i>Journal of Drug Delivery</i> , 2011, 2011, 1-18.	2.5	54
191	Design and characterization of calcium alginate microparticles coated with polycations as protein delivery system. <i>Journal of Microencapsulation</i> , 2011, 28, 614-620.	2.8	12
192	Microcapsules and microcarriers for in situ cell delivery. <i>Advanced Drug Delivery Reviews</i> , 2010, 62, 711-730.	13.7	323
193	Delivery of immunostimulatory monoclonal antibodies by encapsulated hybridoma cells. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1621-1631.	4.2	38
194	Solid lipid nanoparticles as potential tools for gene therapy: In vivo protein expression after intravenous administration. <i>International Journal of Pharmaceutics</i> , 2010, 385, 157-162.	5.2	80
195	Improvement of the monitoring and biosafety of encapsulated cells using the SFGNESTGL triple reporter system. <i>Journal of Controlled Release</i> , 2010, 146, 93-98.	9.9	29
196	Biomaterial-based technologies for brain anti-cancer therapeutics and imaging. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2010, 1806, 96-107.	7.4	42
197	The effect of encapsulated VEGF-secreting cells on brain amyloid load and behavioral impairment in a mouse model of Alzheimer's disease. <i>Biomaterials</i> , 2010, 31, 5608-5618.	11.4	114
198	Biomaterials in Cell Microencapsulation. <i>Advances in Experimental Medicine and Biology</i> , 2010, 670, 5-21.	1.6	73

#	ARTICLE	IF	CITATIONS
199	Recent advances in the use of encapsulated cells for effective delivery of therapeutics. <i>Therapeutic Delivery</i> , 2010, 1, 387-396.	2.2	7
200	Highlights and Trends in Cell Encapsulation. <i>Advances in Experimental Medicine and Biology</i> , 2010, 670, 1-4.	1.6	9
201	Topical resiquimod: a promising adjuvant for vaccine development?. <i>Expert Review of Vaccines</i> , 2010, 9, 23-27.	4.4	14
202	Comparison of the adjuvanticity of two different delivery systems on the induction of humoral and cellular responses to synthetic peptides. <i>Drug Delivery</i> , 2010, 17, 490-499.	5.7	16
203	In vivo evaluation of two new sustained release formulations elaborated by one-step melt granulation: Level A in vitroâ€œin vivo correlation. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2010, 75, 232-237.	4.3	17
204	Epo Delivery by Genetically Engineered C2C12 Myoblasts Immobilized in Microcapsules. <i>Advances in Experimental Medicine and Biology</i> , 2010, 670, 54-67.	1.6	3
205	A proline-rich peptide improves cell transfection of solid lipid nanoparticle-based non-viral vectors. <i>Journal of Controlled Release</i> , 2009, 133, 52-59.	9.9	98
206	Bioactive cell-hydrogel microcapsules for cell-based drug delivery. <i>Journal of Controlled Release</i> , 2009, 135, 203-210.	9.9	94
207	Xenogeneic transplantation of erythropoietin-secreting cells immobilized in microcapsules using transient immunosuppression. <i>Journal of Controlled Release</i> , 2009, 137, 174-178.	9.9	49
208	Cryopreservation based on freezing protocols for the long-term storage of microencapsulated myoblasts. <i>Biomaterials</i> , 2009, 30, 3495-3501.	11.4	46
209	Pharmacokinetics and tissue distribution of Kendine 91, a novel histone deacetylase inhibitor, in mice. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 153-159.	2.3	14
210	Multiscale requirements for bioencapsulation in medicine and biotechnology. <i>Biomaterials</i> , 2009, 30, 2559-2570.	11.4	198
211	Short- and long-term stability study of lyophilized solid lipid nanoparticles for gene therapy. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2009, 71, 181-189.	4.3	109
212	Induction of angiogenesis by implantation of encapsulated cells expressing vegf: A new therapy approach on Alzheimer's disease?. <i>Journal of the Neurological Sciences</i> , 2009, 283, 260.	0.6	0
213	Biomaterials for promoting brain protection, repair and regeneration. <i>Nature Reviews Neuroscience</i> , 2009, 10, 682-692.	10.2	378
214	Polymeric Materials and Formulation Technologies for Modified-Release Tablet Development. <i>Mini-Reviews in Medicinal Chemistry</i> , 2009, 9, 1504-1517.	2.4	3
215	Development and validation of a liquid chromatographyâ€œtandem mass spectrometry for the determination of Kendine 91, a novel histone deacetylase inhibitor, in mice plasma and tissues: Application to a pharmacokinetic study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> . 2008. 870. 109-116.	2.3	7
216	Solid lipid nanoparticles for retinal gene therapy: Transfection and intracellular trafficking in RPE cells. <i>International Journal of Pharmaceutics</i> , 2008, 360, 177-183.	5.2	93

#	ARTICLE	IF	CITATIONS
217	Cell microencapsulation technology: Towards clinical application. <i>Journal of Controlled Release</i> , 2008, 132, 76-83.	9.9	314
218	Population Pharmacokinetics of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy. <i>Clinical Pharmacokinetics</i> , 2008, 47, 173-180.	3.5	56
219	β -Irradiation effects on biopharmaceutical properties of PLGA microspheres loaded with SPf66 synthetic vaccine. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2008, 69, 519-526.	4.3	41
220	Cationic lipids as gene transfer agents: a patent review. <i>Expert Opinion on Therapeutic Patents</i> , 2008, 18, 515-524.	5.0	19
221	Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to <i>Plasmodium falciparum</i> MSP2 long synthetic peptides in mice. <i>Vaccine</i> , 2007, 25, 877-885.	3.8	36
222	In vitro AN69 and Polysulphone Membrane Permeability to Ceftazidime and in vivo Pharmacokinetics during Continuous Renal Replacement Therapies. <i>Chemotherapy</i> , 2007, 53, 194-201.	1.6	27
223	In Vitro Characterization and In Vivo Functionality of Erythropoietin-Secreting Cells Immobilized in Alginate-Poly-Lysine-Alginate Microcapsules. <i>Biomacromolecules</i> , 2007, 8, 3302-3307.	5.4	59
224	Solid lipid nanoparticles: Formulation factors affecting cell transfection capacity. <i>International Journal of Pharmaceutics</i> , 2007, 339, 261-268.	5.2	98
225	Long-term survival of encapsulated GDNF secreting cells implanted within the striatum of parkinsonized rats. <i>International Journal of Pharmaceutics</i> , 2007, 343, 69-78.	5.2	64
226	Encapsulation of Cells in Alginate Gels. <i>Methods in Biotechnology</i> , 2006, , 345-355.	0.2	22
227	Chemistry and the biological response against immunisolating alginate-polycation capsules of different composition. <i>Biomaterials</i> , 2006, 27, 4831-4839.	11.4	99
228	Evaluation of human serum albumin as a substitute of foetal bovine serum for cell culture. <i>International Journal of Pharmaceutics</i> , 2006, 310, 8-14.	5.2	16
229	Development and optimization of a novel sustained-release dextran tablet formulation for propranolol hydrochloride. <i>International Journal of Pharmaceutics</i> , 2006, 317, 32-39.	5.2	51
230	Biocompatibility of alginate-poly-L-lysine microcapsules for cell therapy. <i>Biomaterials</i> , 2006, 27, 3691-3700.	11.4	309
231	In vivo evaluation of EPO-secreting cells immobilized in different alginate-PLL microcapsules. <i>Journal of Controlled Release</i> , 2006, 116, 28-34.	9.9	47
232	The effect of selected parameters of formation on properties of alginate/Ca ²⁺ /oligochitosan capsules. <i>Journal of Chemical Technology and Biotechnology</i> , 2006, 81, 511-518.	3.2	7
233	Elimination of Piperacillin and Tazobactam by Renal Replacement Therapies with AN69 and Polysulfone Hemofilters: Evaluation of the Sieving Coefficient. <i>Blood Purification</i> , 2006, 24, 347-354.	1.8	26
234	Biomedical Applications of Immobilized Cells. <i>Methods in Biotechnology</i> , 2006, , 427-437.	0.2	3

#	ARTICLE	IF	CITATIONS
235	Determination of ceftazidime and cefepime in plasma and dialysate-ultrafiltrate from patients undergoing continuous veno-venous hemodiafiltration by HPLC. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2005, 39, 996-1005.	2.8	30
236	Microcapsules prepared with different biomaterials to immobilize GDNF secreting 3T3 fibroblasts. <i>International Journal of Pharmaceutics</i> , 2005, 293, 1-10.	5.2	20
237	Challenges in Cell Encapsulation. <i>Focus on Biotechnology</i> , 2005, , 185-196.	0.4	6
238	The role of pH dynamics and the Na ⁺ /H ⁺ antiporter in the etiopathogenesis and treatment of cancer. Two faces of the same coin – one single nature. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2005, 1756, 1-24.	7.4	136
239	Quantitation and stability of piperacillin and tazobactam in plasma and ultrafiltrate from patients undergoing continuous venovenous hemofiltration by HPLC. <i>Biomedical Chromatography</i> , 2005, 19, 570-578.	1.7	21
240	Mass transfer characteristics of poly-lysine, poly-ornithine and poly-methylene-co-guanidine membrane coated alginate microcapsules. <i>Journal of Membrane Science</i> , 2005, 254, 249-257.	8.2	9
241	Influence of Renal Function on the Pharmacokinetics of Piperacillin/Tazobactam in Intensive Care Unit Patients During Continuous Venovenous Hemofiltration. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 168-176.	2.0	64
242	Meropenem and Continuous Renal Replacement Therapy: In Vitro Permeability of 2 Continuous Renal Replacement Therapy Membranes and Influence of Patient Renal Function on the Pharmacokinetics in Critically Ill Patients. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 1294-1304.	2.0	50
243	Long-Term Expression of Erythropoietin from Myoblasts Immobilized in Biocompatible and Neovascularized Microcapsules. <i>Molecular Therapy</i> , 2005, 12, 283-289.	8.2	70
244	The influence of cellular seeding density in the microencapsulation of hybridoma cells. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2005, 16, 521-529.	3.5	5
245	Biocompatibility Evaluation of Different Alginates and Alginate-Based Microcapsules. <i>Biomacromolecules</i> , 2005, 6, 927-931.	5.4	109
246	Cefepime and continuous renal replacement therapy (CRRT): In vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients. <i>Clinical Therapeutics</i> , 2005, 27, 599-608.	2.5	52
247	Pharmacokinetic/Pharmacodynamic Evaluation of Antimicrobial Treatments of Orofacial Odontogenic Infections. <i>Clinical Pharmacokinetics</i> , 2005, 44, 305-316.	3.5	14
248	Comparative study of microcapsules elaborated with three polycations (PLL, PDL, PLO) for cell immobilization. <i>Journal of Microencapsulation</i> , 2005, 22, 303-315.	2.8	56
249	Preparation of sustained release hydrophilic matrices by melt granulation in a high-shear mixer. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2005, 8, 132-40.	2.1	18
250	History, challenges and perspectives of cell microencapsulation. <i>Trends in Biotechnology</i> , 2004, 22, 87-92.	9.3	333
251	The search for new \hat{I}^2 -cell sources. <i>Trends in Biotechnology</i> , 2004, 22, 612-613.	9.3	2
252	Enhancing Immunogenicity and Reducing Dose of Microparticulated Synthetic Vaccines: Single Intradermal Administration. <i>Pharmaceutical Research</i> , 2004, 21, 121-126.	3.5	28

#	ARTICLE	IF	CITATIONS
253	Techniques: New approaches to the delivery of biopharmaceuticals. Trends in Pharmacological Sciences, 2004, 25, 382-387.	8.7	87
254	Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles. Vaccine, 2004, 22, 1423-1432.	3.8	83
255	Survival of different cell lines in alginate-agarose microcapsules. European Journal of Pharmaceutical Sciences, 2003, 18, 23-30.	4.0	95
256	Controversies over stem cell research. Trends in Biotechnology, 2003, 21, 109-112.	9.3	15
257	A glimmer of hope for diabetics?. Trends in Biotechnology, 2003, 21, 289-290.	9.3	2
258	New N-Alkyl-1,2-dihydro-2-thioxo-3-pyridinecarbothioamides as Antituberculous Agents with Improved Pharmacokinetics.. ChemInform, 2003, 34, no.	0.0	0
259	Drug delivery in biotechnology: present and future. Current Opinion in Biotechnology, 2003, 14, 659-664.	6.6	198
260	Development and optimisation of alginate-PMCG-alginate microcapsules for cell immobilisation. International Journal of Pharmaceutics, 2003, 259, 57-68.	5.2	67
261	Immune response after oral administration of the encapsulated malaria synthetic peptide SPf66. International Journal of Pharmaceutics, 2003, 260, 273-282.	5.2	43
262	Cell encapsulation: Promise and progress. Nature Medicine, 2003, 9, 104-107.	30.7	546
263	Cell microencapsulation technology for biomedical purposes: novel insights and challenges. Trends in Pharmacological Sciences, 2003, 24, 207-210.	8.7	127
264	Immune responses to orally administered PLGA microparticles: influence of oil vehicles and surfactive agents. Journal of Microencapsulation, 2003, 20, 525-536.	2.8	3
265	Hydrogen ion dynamics and the Na ⁺ /H ⁺ exchanger in cancer angiogenesis and antiangiogenesis. British Journal of Cancer, 2003, 89, 1395-1399.	6.4	35
266	Mass transfer ranking of polylysine, poly-ornithine and poly-methylene-co-guanidine microcapsule membranes using a single low molecular mass marker. Hemijska Industrija, 2003, 57, 626-631.	0.7	2
267	Preparation and stability of agarose microcapsules containing BCG. Journal of Microencapsulation, 2002, 19, 237-244.	2.8	14
268	Remarkably high antibody levels and protection against P. falciparum malaria in Aotus monkeys after a single immunisation of SPf66 encapsulated in PLGA microspheres. Vaccine, 2002, 20, 1707-1710.	3.8	50
269	Influence of dose and immunization route on the serum Ig G antibody response to BSA loaded PLGA microspheres. Vaccine, 2002, 20, 2181-2190.	3.8	41
270	Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. Vaccine, 2002, 21, 67-77.	3.8	255

#	ARTICLE	IF	CITATIONS
271	Encapsulated cell technology: from research to market. Trends in Biotechnology, 2002, 20, 382-387.	9.3	59
272	Release of salbutamol sulphate and ketoprofen enantiomers from matrices containing HPMC and cellulose derivatives. Chirality, 2002, 14, 806-813.	2.6	13
273	Pharmacokinetics and tissue distribution of intravenous pefloxacin for antibiotic prophylaxis in biliary surgery. Biopharmaceutics and Drug Disposition, 2002, 23, 293-300.	1.9	1
274	New N-Alkyl-1,2-dihydro-2-thioxo-3-pyridinecarbothioamides as antituberculous agents with improved pharmacokinetics. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 2541-2544.	2.2	10
275	Development and characterization of solid lipid nanoparticles loaded with magnetite. International Journal of Pharmaceutics, 2002, 233, 149-157.	5.2	55
276	Release of ketoprofen enantiomers from HPMC K100M matricesâ€”diffusion studies. International Journal of Pharmaceutics, 2002, 239, 61-68.	5.2	24
277	Biocompatibility of microcapsules for cell immobilization elaborated with different type of alginates. Biomaterials, 2002, 23, 3825-3831.	11.4	256
278	Biodegradable PLGA microspheres as a delivery system for malaria synthetic peptide SPf66. Vaccine, 2001, 19, 4445-4451.	3.8	55
279	Preliminary Assessment of the Immune Response toOlea europaeaPollen Extracts Encapsulated into PLGA Microspheres. Pharmaceutical Development and Technology, 2001, 6, 621-627.	2.4	13
280	Microencapsulation of an antiâ€”VEâ€”cadherin antibody secreting 1B5 hybridoma cells. Biotechnology and Bioengineering, 2001, 76, 285-294.	3.3	38
281	Effect of aging on the release of salbutamol sulfate from lipid matrices. International Journal of Pharmaceutics, 2000, 208, 13-21.	5.2	23
282	Edelfosine, apoptosis, MDR and Na ⁺ /H ⁺ exchanger: induction mechanisms and treatment implications. Apoptosis: an International Journal on Programmed Cell Death, 2000, 5, 87-89.	4.9	18
283	Synthesis and in Vitro Anti-MycobacteriumActivity ofN-Alkyl-1,2-dihydro-2-thioxo-3-pyridinecarbothioamides. Preliminary Toxicity and Pharmacokinetic Evaluation. Journal of Medicinal Chemistry, 2000, 43, 199-204.	6.4	27
284	Enhanced immune response after subcutaneous and oral immunization with biodegradable PLGA microspheres. Journal of Controlled Release, 1998, 56, 63-73.	9.9	93
285	Release of salbutamol sulfate enantiomers from hydroxypropylmethylcellulose matrices. International Journal of Pharmaceutics, 1998, 161, 37-43.	5.2	20
286	Stability of BSA encapsulated into PLGA microspheres using PAGE and capillary electrophoresis. International Journal of Pharmaceutics, 1998, 169, 45-54.	5.2	54
287	Age and sex dependent pharmacokinetics of cyclosporine in the rat after a single intravenous dose. International Journal of Pharmaceutics, 1998, 174, 9-18.	5.2	9
288	Pharmacokinetics and Tissue Distribution of Intravenous Ofloxacin for Antibiotic Prophylaxis in Biliary Surgery. Clinical Drug Investigation, 1998, 15, 491-496.	2.2	6

#	ARTICLE	IF	CITATIONS
289	Determination of salbutamol enantiomers by high-performance capillary electrophoresis and its application to dissolution assays. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1997, 16, 357-366.	2.8	27
290	Correlation of "in vitro" release and "in vivo" absorption characteristics of four salbutamol sulphate formulations. <i>International Journal of Pharmaceutics</i> , 1996, 139, 45-52.	5.2	8
291	Influence of Partial Hepatectomy on Theophylline Pharmacokinetics in Rats. <i>Journal of Pharmaceutical Sciences</i> , 1996, 85, 1133-1135.	3.3	5
292	On the employment of Î»-carrageenan in a matrix system. II. Î»-Carrageenan and hydroxypropylmethylcellulose mixtures. <i>Journal of Controlled Release</i> , 1994, 30, 175-182.	9.9	69
293	Interspecies scaling of cimetidine-theophylline pharmacokinetic interaction: interspecies scaling in pharmacokinetic interactions. <i>Pharmaceutical Research</i> , 1994, 11, 945-950.	3.5	27
294	On the employment of Î»-carrageenan in a matrix system. I. Sensitivity to dissolution medium and comparison with Na carboxymethylcellulose and xanthan gum. <i>Journal of Controlled Release</i> , 1993, 26, 119-127.	9.9	72
295	Rheological behaviour of hydrophilic polymers and drug release from erodible matrices. <i>Journal of Controlled Release</i> , 1992, 18, 205-212.	9.9	47
296	Pharmacokinetic-Pharmacodynamic Modeling: Time-Dependent Protein Binding" An Alternative Interpretation of Clockwise and Counterclockwise Hysteresis. <i>Journal of Pharmaceutical Sciences</i> , 1992, 81, 232-236.	3.3	12
297	Pharmacokinetics of cefazoline and dibenzylamine administered in a sustained drug delivery system to healthy volunteers. <i>International Journal of Pharmaceutics</i> , 1991, 67, 259-264.	5.2	0
298	PHARMACOKINETICS AND DISTRIBUTION OF KETAMINE AFTER EXTRADURAL ADMINISTRATION TO DOGS. <i>British Journal of Anaesthesia</i> , 1991, 67, 310-316.	3.4	46
299	Pharmacokinetics of dibenzylamine administered in a sustained drug delivery system with cefazolin. <i>Biopharmaceutics and Drug Disposition</i> , 1990, 11, 797-806.	1.9	1
300	PHARMACOKINETICS OF RECTAL KETAMINE IN CHILDREN. <i>British Journal of Anaesthesia</i> , 1989, 63, 671-674.	3.4	28
301	Determination of low concentrations of dibenzylamine in human plasma and urine by gas chromatography with a nitrogen-phosphorus detector. <i>Biomedical Applications</i> , 1989, 490, 206-212.	1.7	6
302	Choice of optimum pharmacokinetic model of orally administered paracetamol. <i>Biopharmaceutics and Drug Disposition</i> , 1988, 9, 389-396.	1.9	4
303	The biotransformation kinetics of Ketamine" in vitro" in rabbit liver and lung microsome fractions. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 1986, 11, 9-16.	1.6	5
304	Kinetics of ketamine and its metabolites in rabbits with normal and impaired renal function. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 1985, 10, 33-39.	1.6	21
305	In vitro binding of ketamine to human serum albumin. <i>International Journal of Pharmaceutics</i> , 1985, 25, 147-153.	5.2	2